A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

NCT05228496 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Small Cell

Interventions

DRUG: Tislelizumab
DRUG: Sitravatinib

Sponsor

Zhejiang Cancer Hospital